MMP inhibitors: Experimental and clinical studies

International Journal of Biological Markers

Volumn 14, Issue 4, 1999, Pages 232-238

  Belotti, D ^a   Paganoni, P ^a   Giavazzi, R ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

Markers; Metalloproteases; MMP inhibitors

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; BATIMASTAT; CARBOPLATIN; CGS 27023A; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PACLITAXEL; PRINOMASTAT; TANOMASTAT;

ANGIOGENESIS; ARTHRALGIA; BODY FLUID; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; MUSCULOSKELETAL DISEASE; PAIN; PERITONITIS; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 0033388462     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089901400406     Document Type: Conference Paper

References (64)

1. DeClerck YA, Imren S, Montgomery AMP, Mueller BM, Reisfeld RA, Laug WE. Proteases and protease inhibitors in tumor progression. Adv Exp Med Biol 1997; 425: 89-97.
2. Woessner JF Jr. Matrix metalloproteinases and their inhibitor in connective tissue remodeling. FASEB J 1991; 5: 2145-54.
3. Kleiner DEJ, Stetler-Stevenson WG. Structural biochemistry and activation of matrix metalloproteases. Curr Opin Cell Biol 1993; 5: 891-7.
4. Matrisian LM, Hogan BL. Growth factor-regulated proteases and extracellular matrix remodeling during mammalian development. Curr Top Dev Biol 1990; 24: 219-59.
5. Opdenakker G, Van Damme J. Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer. Cytokine 1992; 4: 251-8.
6. Mauviel A. Cytokine regulation of metalloproteinase gene expression. J Cell Biochem 1993; 53: 288-95.
7. Matrisian LM, Leroy P, Ruhlmann C, Gesnel MC, Breathnach R. Isolation of the oncogene and epidermal growth factor-induced transin gene: complex control in rat fibroblasts. Molec Cell Biol 1986; 6: 1679-86.
8. Overall CM, Wrana JL, Sodek J. Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem 1991; 266: 14064-71.
9. Delany AM, Brinckerhoff CE. Post-transcriptional regulation of collagenase and stromelysin gene expression by epidermal growth factor and dexamethasone in cultured human fibroblasts. J Cell Biochem 1992; 50: 400-10.
10. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997; 15: 61-75.
11. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995; 270: 5331-8.
12. MacDougall JR, Matrisian LM. Contributions of tumors and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 1995; 14: 351-62.
13. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997; 91: 439-42.
14. Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 1998; 94: 353-62.
15. Azzam HS, Arand G, Lippman ME, Thompson EW. Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst 1993; 85: 1758-64.
16. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 1996; 271: 10079-86.
17. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260-70.
18. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 1996; 56: 190-6.
19. Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 1993; 85: 574-8.
20. Nguyen M, Arkell J, Jackson CJ. Active and tissue inhibitor of matrix metalloproteinase-free gelatinase B accumulates within human microvascular endothelial vesicles. J Biol Chem 1998; 273: 5400-4.
21. Gress TM, Muller-Pillasch F, Lerch MM, Friess H, Buchler M, Adler G. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62: 407-13.
22. Fishman DA, Bafetti LM, Banionis S, Kearns AS, Chilukuri K, Stack MS. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma. Cancer 1997; 80: 1457-63.
23. Afzal S, Lalani EN, Poulsom R, et al. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Human Pathol 1998; 29: 155-65.
24. Naylor MS, Stamp GW, Davies BD, Balkwill FR. Expression and activity of MMPs and their regulators in ovarian cancer. Int J Cancer 1994; 58: 50-6.
25. Uria JA, Stahle-Backdahl M, Seiki M, Fueyo A, Lopez-Otin C. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res 1997; 57: 4882-8.
26. Shibata K, Kikkawa F, Nawa A, Suganuma N, Hamaguchi M. Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines. Cancer Res 1997; 57: 5416-20.
27. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: A review of anti-tumor activity. Ann Oncol 1995; 6: 967-74.
28. Brown PD. Clinical trials of a low molecular weight matrix metalloproteinase inhibitor in cancer. Ann NY Acad Sci 1994; 732: 217-21.
29. Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997; 385: 733-6.
30. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-33.
31. Gonnella NC, Li YC, Zhang X, Paris CG. Bioactive conformation of a potent stromelysin inhibitor determined by X-nucleus filtered and multidimensional NMR spectroscopy. Bioorg Med Chem 1997; 5: 2193-201.
32. Hibner B, Card A, Flynn C, et al. BAY 12-9566, a novel, biphenyl matrix metalloproteinase inhibitor, demonstrates anti-invasive and anti-angiogenic properties. Proc Am Ass Cancer Res 1998; 39: 302.
33. Chirivi R, Garofalo A, Crimmin MJ, et al. Inhibition of the metastatic spread and growth of B16-B16 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 1994; 58: 460-4.
34. Taraboletti G, Garofalo A, Belotti D, et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995; 87: 293-8.
35. Sledge GWJ, Qulali M, Goulet R, Bone EA, Fife R. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 1995; 87: 1546-50.
36. Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995; 55: 3629-33.
37. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumour growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994; 54: 4726-8.
38. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993; 53:2087-91.
39. Giavazzi R, Garofalo A, Ferri C, et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res 1998; 4: 985-92.
40. Beattie GJ, Smyth G.J., Smyth JF. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 1998; 4: 1899-902.
41. Praga-Wojtowicz S, Torri J, Johnson M, et al. Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 1998; 16: 2150-6.
42. Flynn C, Bull C, Eberwein D, Matherne C, Hibner B. Anti-metastatic activity of BAY12-9566 in a human colon carcinoma HCT116 orthotopic model. Proc Am Ass Cancer Res 1998; 39: 301 (abstract).
43. Bull C, Flynn C, Eberwein D, Casazza AM, Carter CA, Hibner B. Activity of the biphenyl matrix metalloproteinase inhibitor BAY12-9566 in murine in vivo models. Proc Am Ass Cancer Res 1998; 39: 302 (abstract).
44. Gatto C, Rieppi M, Borsotti P, et al. BAY-12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res 1999; (in press).
45. Hirte H, Goel R, Bennet K, Elias I, Shah A, Seymour L. Phase I study of the matrix metalloprotease inhibitor (MMPI) BAY12-9566 in patients with advanced cancer. Ann Oncol 1998; 9 (Suppl 2): 75 (abstract).
46. Tolcher A, Rowinsky EK, Rizzo J, et al. A phase I and pharmacokinetic study of the oral matrix metalloprotein-ase inhibitor Bay-129566 in combination with paclitaxel and carboplatin. Proc ASCO 1999; 18: 160a (abstract).
47. Shalinsky DR, Brekken J, Zou H, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann NY Acad Sci 1999; 878: 236-70.
48. Price A, Shi Q, Morris D, et al. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res 1999; 5: 845-54.
49. Hande K, Wilding G, Ripple G, et al. A phase I study of AG3340, a matrix metalloprotease (MMP) inhibitor, in patients having advanced cancer. Ann Oncol 1998; 9 (Suppl 2): 74 (abstract).
50. Wood JM, Muller M, Schnell C, et al. CGS 27023A, a potent and orally active matrix metalloprotease inhibitor with antitumor activity. Proc Am Ass Cancer Res 1998; 39: 83 (abstract).
51. Levitt NC, Eskens F, Propper DJ, et al. A phase one pharmacokinetic study of CGS27023A, a matrix metallo-proteinase inhibitor. Proc ASCO 1998; 17: 213a (abstract).
52. Page JG, Rogers TS, Fulton RB, et al. Toxicity of COL-3 to rats and monkeys. Proc Am Ass Cancer Res 1998; 39: 596 (abstract).
53. Gohji K, Fujimoto N, Hara I, et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 1998; 79: 96-101.
54. Jung K, Laube C, Lein M, et al. Matrix metalloproteinase-2 in blood does not indicate the progression of prostate cancer. Int J Cancer 1998; 78: 392-3.
55. Zucker S, Lysik RM, Zarrabi M H, Moll U. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993; 53: 140-6.
56. Iizasa T, Fujisawa T, Suzuki M, et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 1999; 5: 149-53.
57. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 1998; 58: 1395-9.
58. Hanemaaijer R, Sier CF, Visser H, et al. MMP-9 activity in urine from patients with various tumors, as measured by a novel MMP activity assay using modified urokinase as a substrate. Ann NY Acad Sci 1999; 878: 141-9.
59. Fujimoto N, Mouri N, Iwata K, Ohuchi E, Okada Y, Hayakawa T. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clinica Chimica Acta 1993; 221: 91-103.
60. Garbisa S, Scagliotti G, Masiero L, et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 1992; 52: 4548-9.
61. Cooksley S, Hipkiss JB, Tickle SP, et al. Immunoassays for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes. Matrix 1990; 10: 285-91.
62. Clark IM, Powell LK, Wright JK, Cawston TE, Hazleman B. Monoclonal antibodies against human fibroblast collagenase and the design of an enzyme-linked immunosorbent assay to measure total collagenase. Matrix 1999; 12: 475-80.
63. Moscatelli D, Rifkin DB. Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta 1988; 948: 67-84.
64. Zucker S, Hymowitz M, Conner C, et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann NY Acad Sci 1999; 878: 212-27.